A British study, involving 5,500 children and published in the latest issue of PLoS Medicine, used accurate methods to measure the “fat mass” of the children and the amount of physical activity they were taking. The researchers, based at the University of Bristol, concluded that low levels of activity, particularly moderate and vigorous activity, play an important role in the development of obesity.
Disrupt the gene that regulates the biological clocks in mice and they become manic, exhibiting behaviors similar to humans with bipolar disorder, UT Southwestern Medical Center researchers have found.
New non-toxic and targeted therapies for metastatic breast and ovarian cancers may now be possible, thanks to a discovery by a team of researchers at the University of British Columbia.
Women who had more body fat during their pregnancy or are overweight tended to have fatter babies, revealed by British researchers. The study based on information gathered from 448 women before and during pregnancy.
Scientists at the University of Manchester believe injections of tiny sponge-like particles could provide an alternative to major surgery in the treatment of chronic lower back pain.
Stage, screen and film actress Delta Burke is leading the BYETTA Let’s Talk campaign, sponsored by Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY).
Scientists at the Institute for Stem Cell Biology and Medicine at UCLA received two comprehensive research grants from the state as part of the second round of funding for embryonic stem cell research since voters approved Proposition 71 in November 2004.
Many would assume that “mounting an immune response” or “having your body fight the cancer” is a good thing. Now, research at the University of California, San Diego (UCSD) School of Medicine strongly suggests that inflammation associated with the progression of tumors actually plays a key role in the metastasis of prostate cancer.
A single surgery to remove cancer from both the colon and the liver to which it has spread may be better in some cases than the current standard treatment of two separate surgeries with chemotherapy in between, according to a study led by Duke University Medical Center researchers.
The U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death. Soliris is classified as an Orphan Drug and is a new molecular entity containing an ingredient not previously marketed in the United States.